Inclusion Criteria:

          -  Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia)
             and has failed one or two prior standard induction attempts. Failure is defined as:

               -  ≥ 30% bone marrow blasts in a bone marrow with at least 20% cellularity at
                  mid-cycle bone marrow biopsy or

               -  residual AML on ~ day 28 bone marrow biopsy by morphology, flow, PCR or FISH

          -  AML that progressed out of myelodysplastic syndrome (MDS) is eligible if the patient
             did not receive treatment directed at the MDS.

          -  Patients enrolling after only 1 failed induction attempt must meet at least one of the
             following additional eligibility criteria of high risk:

               -  ≥ 60 years of age

               -  adverse cytogenetics or molecular characteristics

                    -  (inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1

                    -  t(6;9)(p23;q34); DEK-NUP214

                    -  t(v;11)(v;q23); MLL rearranged

                    -  -5 or del(5q); -7; abnl(17p); complex karyotype

          -  Persons receiving a "non-standard" induction (i.e. one containing investigational
             agent(s)) will be considered for eligibility by Miltenyi on a case by case basis.

          -  Use of hydroxyurea is permitted to control blasts until the day chemotherapy is
             started.

          -  A history of AML related CNS involvement is allowed if most recent CSF analysis is
             negative at least 2 weeks prior to study treatment.

          -  ≥ 18 and <75 years of age

          -  Karnofsky performance status ≥ 60% (appendix IV)

          -  HLA-haploidentical related donor (aged 12 to 70 years) with donor/recipient match
             based on a minimum of intermediate resolution DNA based Class I typing of the A,B and
             C locus - refer to section 5 for donor selection.

          -  Adequate organ function within 14 days of study registration (30 days for pulmonary
             and cardiac) defined as:

               -  Creatinine: ≤ 2.0 mg/dL

               -  Hepatic: SGOT and SGPT < 5 x upper limit of institutional normal (ULN)

               -  Pulmonary: oxygen saturation ≥ 90% on room air

               -  Cardiac: LVEF ≥ 40% by echocardiogram, MUGA or cardiac MRI, no uncontrolled
                  angina, uncontrolled atrial or ventricular arrhythmias, or evidence of acute
                  ischemia or active conduction system abnormalities (rate controlled a-fib is not
                  an exclusion)

          -  Ability to be off prednisone and other immunosuppressive drugs for at least 3 days
             prior to the NK cell infusion (excluding preparative regimen pre-meds)

          -  Sexually active females of childbearing potential and males with partners of child
             bearing potential must agree to use appropriate birth control precautions during the
             study and for 3 months after the NK cell infusion

          -  Voluntary written consent prior to the performance of any research related procedures

        Exclusion Criteria:

          -  Pregnant or lactating as the treatments used in this study includes drugs that are FDA
             Pregnancy Category D - Positive evidence of human fetal risk based on adverse reaction
             data from investigational or marketing experience or studies in humans. Women of child
             bearing potential must have a negative pregnancy test within 14 days of study
             registration.

          -  Acute leukemias of ambiguous lineage

          -  AML that transformed from previously treated myelodysplastic syndromes

          -  Untreated CNS leukemia

          -  Prior hematopoietic transplant

          -  New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan
             that has not been cleared by Pulmonary. Infiltrates attributed to infection must be
             stable/improving (with associated clinical improvement) after 1 week of appropriate
             therapy (4 weeks for presumed or documented fungal infections)

          -  Uncontrolled bacterial, fungal, or viral infections including HIV - chronic
             asymptomatic viral hepatitis is allowed

          -  Known hypersensitivity to one or more of the study agents